Solasta Ventures
Venture capitalBoston · Seed–Series C · 8 people tracked
Also known as SOLASTA VENTURES, INC.
Investment thesis
Solasta Ventures focuses on healthcare and life sciences, investing in companies working to advance medicine. The team brings more than 30 years of combined experience across healthcare investments and drug development, and invites founders whose mission aligns with advancing medicine to connect.
Source: firm website, verified Aug 3, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 17 of 30 portfolio companiesBiotech ×16Healthtech ×5Medical Devices ×4Deep Tech ×3AI & Machine Learning ×1B2B Marketplaces ×1Digital Health ×1E-commerce ×1
HQs:United States×13
Investments · 30 tracked
founders shown can be your intro pathArvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology.
BiotechNew Haven, US
Stephen Squinto(Director)Liam Ratcliffe(Director)Andrew Levin(Director)Sean Cassidy(Executive Officer)Jonathan Soderstrom(Director)Brad Margus(Director)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Ed Mathers(Director)Chau Khuong(Director)Bharatt Chowrira(Executive Officer)Ankit Mahadevia(Director)Michael Sheahan(Executive Officer)Peter Barrett(Director)
BiotechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Peter Dudek(Director)David Grayzel(Director)Nancy Hong(Director)Rachel Humphrey(Director)
Trefoil Therapeutics develops ophthalmologic drugs, with a team focused on drug development and commercialization in the eye-care field.
BiotechHealthtechSan Diego, US
Ralph Bradshaw(Director)Christy Shaffer(Director)Schalon Newton(Executive Officer)David Eveleth(Executive Officer, Director)
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Lewis T. Rusty Williams(Director)Jill Carroll(Director)David Lubner(Director)Ali Behbahani(Director)Rami Elghandour(Executive Officer, Director)
Axonis Therapeutics develops medicines targeting KCC2 to restore inhibition in the brain, with a focus on treating neurological disorders including epilepsy and pain.
BiotechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Executive Officer, Director)
BoardCorey . Goodman(Director)Jonathan Leff(Director)Raymond J. Kelleher(Director)
BiotechBerkeley, US
Ran Geng(Director)Winnie Wan(Director)Genine A. Winslow(Executive Officer, Director)
BiotechAlpharetta, US
William Humphries(Director)Gerald Cagle, Ph.D.(Director)Evgeny Zaytsev(Director)Derek Yoon(Director)Christy L. Shaffer, Ph.D.(Director)Charles Deignan(Executive Officer)
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Timothy Sullivan(Director)Peter Kolchinsky(Director)Mark A. Velleca(Executive Officer, Director)Glenn Muir(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Laura Brass(Director)Amanda Wagner(Executive Officer)Kai Wucherpfennig(Director)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)Dr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)Christopher J. Kirk(Executive Officer, Director)
BiotechAustin, US
Orions Bio discovers, designs and engineers molecules that connect proteins on and within cells to reprogram disease-driving processes or activate immune responses.
BiotechDeep TechHealthtech
Griet Vanpoucke, Ph.D.(Director)Steven R. Gullans, Ph.D.(Director)Nikolai Kley, Ph.D.(Executive Officer, Director)
EvolveImmune develops trispecific T cell engagers with integrated CD2 costimulation through its EVOLVE platform to address cancer cell resistance to immunotherapies.
BiotechHealthtech
Frequently asked questions
- What stage does Solasta Ventures invest at?
- Solasta Ventures invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Solasta Ventures focus on?
- Solasta Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Solasta Ventures located?
- Solasta Ventures is headquartered in Boston, US.
Co-investors · 3
Madrona Venture Group is an early-stage venture capital firm that backs founding teams at seed, early, and acceleration stages, primarily in Seattle, the Bay Area, and beyond.
Intel Capital is the corporate venture capital arm associated with Intel, investing in and supporting technology companies as they scale.
Propel Venture Partners is an early-stage venture capital firm that backs founders building companies for the new economy.
Firms observed investing alongside Solasta Ventures, from public investor directories. Shared companies are the overlap with Solasta Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.